Clinical trials in Cologne – page 3

639 clinical trials in Cologne, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Cologne at a glance

639

clinical trials

Research sites4

Quick filters

639 trials in Cologne

Open in trial search

Non-small cell lung cancer metastatic

Recruiting

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:BMS-986340
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Staphylococcal bacteraemia

Recruiting

Safety and Pharmacokinetics of MIB2 (StaphAcute) in Healthy Volunteers and Patients with Staphylococcus aureus Bacteremia

Registered drug

Safety and Pharmacokinetics of MIB2 (StaphAcute) in Healthy Volunteers and Patients with Staphylococcus aureus Bacteremia

Registered drug

Germany

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Sodium Chloride
Sponsor:University Of Cologne

Contact Research Centre

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Dementia Alzheimer's type

Recruiting

A study of SAR448851 with florquinitau (18F) to assess safety and effectiveness in early Alzheimer’s disease

Investigational

A study of SAR448851 with florquinitau (18F) to assess safety and effectiveness in early Alzheimer’s disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Florquinitau (18F)
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:BeOne Medicines I GmbH

Contact Research Centre

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Obesity

Recruiting

Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes

Investigational

Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Small cell lung cancer

Recruiting

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Topotecan
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Rheumatoid arthritis

Recruiting

Safety and Efficacy of BMS-986528 with Tocilizumab in Patients with Refractory Rheumatoid Arthritis: A Phase 1/2a Open‑Label Study

Registered drugNo placebo

Safety and Efficacy of BMS-986528 with Tocilizumab in Patients with Refractory Rheumatoid Arthritis: A Phase 1/2a Open‑Label Study

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Tocilizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

HIV infection

Recruiting

Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study

Registered drugNo placebo

Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abacavir
Sponsor:Gilead Sciences Inc.

Contact Research Centre

HIV infection

Recruiting

Switching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1

Registered drugNo placebo

Switching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cabotegravir
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Cologne

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for diffuse large B-cell lymphoma, multiple myeloma, and various solid tumors. Research aims to evaluate new combination therapies and targeted treatments.

Lymphoma and Blood Cancers
Advanced Breast Cancer
Non-Small Cell Lung Cancer

Multiple studies are investigating novel drug combinations and immunotherapy approaches.

02 Autoimmune Conditions

Comprehensive research into autoimmune disorders, with particular focus on Sjögren's Disease and rheumatoid arthritis. Studies evaluate new biological therapies and treatment approaches.

Inflammatory Myopathies
Primary Sjögren's Disease
Rheumatic Diseases

Trials aim to improve disease management and patient outcomes through innovative therapies.

03 Infectious Diseases

Groundbreaking research in infectious disease management, including studies on HIV-1 treatment and drug-resistant infections. Focus on developing new therapeutic approaches and treatment strategies.

HIV Treatment Innovation
Antimicrobial Resistance
Pneumococcal Disease

Studies explore novel treatment regimens and preventive approaches.

Back to Germany All countries

Clinical trials in Cologne – page 3

639 trials in Cologne

Non-small cell lung cancer metastatic

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Staphylococcal bacteraemia

Safety and Pharmacokinetics of MIB2 (StaphAcute) in Healthy Volunteers and Patients with Staphylococcus aureus Bacteremia

Gastrointestinal stromal tumour

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

Dementia Alzheimer's type

A study of SAR448851 with florquinitau (18F) to assess safety and effectiveness in early Alzheimer’s disease

Hormone receptor positive HER2 negative breast cancer

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Heart failure with preserved ejection fraction

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Obesity

Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes

Small cell lung cancer

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Oesophageal adenocarcinoma

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Rheumatoid arthritis

Safety and Efficacy of BMS-986528 with Tocilizumab in Patients with Refractory Rheumatoid Arthritis: A Phase 1/2a Open‑Label Study

HIV infection

Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study

HIV infection

Switching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1

Filter the trials

Other cities in Germany

Clinical research in Cologne

Prefer not to search? Our Concierge searches the trials for you.

Clinical trials in Cologne – page 3

639 trials in Cologne

Other cities in Germany

Related

Clinical research in Cologne

Prefer not to search? Our Concierge searches the trials for you.